Organization
University of Glasgow
1 clinical trial
16 abstracts
Abstract
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,
Abstract
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.Org: Euromed service, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, The University of Texas MD Anderson Cancer Center, British Columbia Cancer Agency, Asan Medical Center,
Clinical trial
Role of Gastrointestinal Appetite Hormones in the Success of Body Mass Loss Interventions Based on Exercise Combined With Calorie-restricted Diets With Different Fat and Carbohydrate ContentStatus: Recruiting, Estimated PCD: 2024-12-01
Abstract
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vanderbilt University Medical Center, Jewish General Hospital Stroll Cancer Prevention Centre, Queensland Health, Ramón y Cajal University Hospital,
Abstract
The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.Org: University of Leeds, University of Glasgow, University of Birmingham, Patient representative, Christie NHS Foundation Trust, Manchester, United Kingdom,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
A NOVEL SMALL MOLECULE, MBS2133, MODULATES OSTEOCLAST PRE-CURSOR METABOLISM TO INHIBIT OSTEOCLAST DIFFERENTIATION: AN ALTERNATIVE THERAPY FOR OSTEOLYTIC PATHOLOGY IN RAOrg: Istesso Ltd, London, United Kingdom, Johnson and Johnson Innovation, London, United Kingdom, University of Glasgow, University of Liverpool, University of Aberdeen,
Abstract
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART) study: baseline characteristics of the randomised patient populationOrg: MEMO Research, University of Dundee, Dundee The Robertson Centre for Biostatistics, University of Glasgow, Glasgow University of Nottingham,
Abstract
A THREE YEAR RETROSPECTIVE SURVEY OF FOOT AND ANKLE ULTRASOUND INVESTIGATIONS UNDERTAKEN IN A RHEUMATOLOGY OUT-PATIENT CLINICOrg: Glasgow Caledonian University, Glasgow Royal Infirmary, University of Glasgow,
Abstract
ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIALOrg: King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, University of Birmingham, Sandwell and West Birmingham NHS Trust, Catholic University of the Sacred Heart, Rome, Italy,
Abstract
ABATACEPT INHIBITS THE GENERATION OF ANTIGEN-SPECIFIC T FOLLICULAR HELPER CELLS AND SUPPRESSES B CELL RESPONSES AND THE BREACH OF SELF-TOLERANCE IN VIVO Org: Bristol Myers Squibb Co. Research and Development, University of Glasgow,
Abstract
ANTI-INFLAMMATORY COMPLEXES INHIBIT THE DEVELOPMENT COLLAGEN-INDUCED ARTHRITIS Org: University of Glasgow, University of California San Diego,
Abstract
BARICITINIB MAY REDUCE CO-EXISTING FIBROMYALGIA IN PEOPLE WITH RHEUMATOID ARTHRITIS: AN ULTRA-HIGH RESOLUTION MRI BRAIN STUDYOrg: University of Glasgow, University of Michigan,
Abstract
BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDYOrg: UCB Pharma, Brigham and Women’s Hospital, Sorbonne Université, University of Rochester Medical School, University of Oxford,
Abstract
BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDYOrg: UCB Pharma, Brigham and Women's Hospital/Massachusetts General Hospital, University of Glasgow, University of Oxford, Oxford University Hospitals NHS Trust,